Elutia

Elutia (Nasdaq: ELUT) will present at the 16th Annual LD Micro Invitational on May 18, 2026 in Los Angeles — sharing how our drug-eluting biomatrix technology is working to reduce post-surgical infection in implant-based breast reconstruction. 📅 May 18, 2026 · 11:30 a.m. PT 📍 Luxe Sunset Boulevard Hotel, Los Angeles 🎤 Dr. Randy Mills, CEO & Matt Ferguson, CFO Infection remains a leading cause of complications and revision surgeries for patients undergoing breast reconstruction after mastectomy. We are focused on changing that. During the presentation, Dr. Mills and Mr. Ferguson will discuss Elutia's clinical focus, commercial progress, and the broader mission of humanizing medicine so patients can thrive without compromise. Investors are also invited to schedule one-on-one meetings with Elutia leadership throughout the day. Live webcast: https://ldmicroevents.com/ Register or book a 1:1 meeting: https://lnkd.in/grx-AHDu #Elutia #ELUT #LDMicro #MedTech #BreastReconstruction #DrugElutingBiomatrix #InvestorRelations #MedicineHumanized #Biotech #MicroCap

Each year, more than 150,000 breast reconstruction procedures are performed in the U.S.—yet one in three patients still faces a serious complication. That’s not good enough We’re working to change it.   🎯 We’re hiring a Vice President of Operations (Site Head) in Gaithersburg—leading the build, launch, and scale of a complex GMP manufacturing facility and joining our leadership team.   🏗️ This is an opportunity to build something exceptional—scaling it with urgency, discipline, and grit in a highly regulated environment where the stakes are high and the work matters.   At Elutia, how we work matters as much as what we build. As a certified Great Place To Work, our culture is grounded in our CRU values—Contagiously Confident, Ridiculously Relentless, and Unanimously United.   This role is built for someone who is: ✔️ All in on the mission ✔️ Confident, not arrogant ✔️ Relentless in the face of obstacles ✔️ Team-first and focused on outcomes over status ✔️ Energized by hard problems and high standards   If you’re ready to build something that matters, we’d love to hear from you. Reach out directly or Apply here: https://lnkd.in/g2ecKGuh #Hiring #OperationsLeadership #Manufacturing #GreatPlaceToWork

One in three women undergoing breast reconstruction after cancer experiences a serious complication.   That statistic underscores why innovation in reconstructive surgery is urgently needed.   We’re excited to welcome Pete Ligotti to Elutia as our new Chief Commercial Officer. Pete joins us to lead the commercial strategy for NXT-41x, our next-generation drug-eluting biomatrix designed to reduce the unacceptable infection rate and improve outcomes in breast reconstruction.   Throughout his career, Pete has focused on bringing forward innovations that meaningfully improve patient outcomes. His leadership will be instrumental as we advance our mission to humanize medicine so patients can thrive without compromise.   With deep experience in commercial strategy and market development, Pete will help prepare Elutia for the anticipated launch of NXT-41x and work to establish a new drug-eluting standard of care in reconstructive surgery.   Welcome to the CRU, Pete.

We’re proud to share that Elutia has earned Great Place to Work® Certification, a recognition driven entirely by employee feedback. It reflects our high-performing culture built on trust, innovation, and disciplined execution. This recognition belongs to the people behind the work: teams who set a high bar, stay committed to the mission, and deliver impact every day. We’re proud of the culture we’ve built—and even prouder of the CRU who bring it to life. High standards. Real impact. Thrive without compromise. We are Elutia. Explore opportunities at Elutia https://lnkd.in/gCsy8_5q Check out our press release: https://lnkd.in/gTDtU2Gp #Elutia #GreatPlaceToWork #HighPerformance

JPM Week is underway and we appreciate the thoughtful conversations around Elutia's strategy and our focused approach to advancing next-generation drug-eluting biomatrix technologies. Our CRU is energized by the engagement around addressing infection and healing challenges in implant-based procedures, particularly in breast reconstruction where infection remains one of the biggest barriers to recovery, occurring in 15–20% of cases. #JPM2026 #HumanizingMedicine

We're on in less than 1 hour! Join our online session at 10:00 a.m. PT / 1:00 p.m. ET on tackling the 1-in-3 complication rate in breast reconstruction at the Global BioInnovation Forum. Webcast of the event will be on the “Investors” section of the Elutia website at https://lnkd.in/esKmKqwU.

Today Elutia provides a corporate update and development milestones for NXT-41x, its next-generation antibiotic-eluting biomatrix program in plastic and reconstructive surgery. NXT-41x is Elutia’s next-generation antibiotic-eluting biomatrix, built on the Company’s technology platform that was clinically and commercially validated with EluPro, indicated for use with pacemaker placement. From our CEO, C. Randal Mills, Ph.D.:  “The success of EluPro was transformational for Elutia. It validated the technical and commercial capability of our drug-eluting platform and enabled us to enter plastic and reconstructive surgery, where complication rates in breast reconstruction remain unacceptably high. We enter 2026 with a strong balance sheet and the capital required to develop and commercialize NXT-41x. With an experienced team and a focused strategy, we are positioned to execute and advance our mission so that patients can thrive without compromise.”

Looking forward to the Global BioInnovation Forum on Jan 13th, when our CEO, C. Randal Mills, Ph.D. and Dr. Christopher Reid, UC San Diego Health, discuss emerging approaches to address infectious complications in breast reconstruction. Join us virtually on Tuesday at 10am PT/1pm ET. Link in comments for more details. #HumanizingMedicine

Elutia will be in San Francisco for the JP Morgan Healthcare Conference next week, meeting with investors and partners. With a strong financial position and a proven drug-eluting biomatrix platform, we are strategically focused on advancing NXT-41x to address the root causes of infection following breast reconstruction procedures. We look forward to discussion on our strategy, leadership and disciplined execution in addressing significant unmet clinical needs. #JPM2026